Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.550
-0.170 (-6.25%)
At close: Apr 2, 2026, 4:00 PM EDT
2.680
+0.130 (5.10%)
After-hours: Apr 2, 2026, 7:52 PM EDT
Anixa Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
85.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Oct 31, 2025 | - | - | - |
| Oct 31, 2024 | - | - | - |
| Oct 31, 2023 | 210.00K | - | - |
| Oct 31, 2022 | - | - | - |
| Oct 31, 2021 | 512.00K | - | - |
| Oct 31, 2020 | - | - | - |
| Oct 31, 2019 | 250.00K | -862.50K | -77.53% |
| Oct 31, 2018 | 1.11M | 750.00K | 206.90% |
| Oct 31, 2017 | 362.50K | 62.50K | 20.83% |
| Oct 31, 2016 | 300.00K | -8.96M | -96.76% |
| Oct 31, 2015 | 9.26M | 5.59M | 152.36% |
| Oct 31, 2014 | 3.67M | 3.28M | 843.12% |
| Oct 31, 2013 | 388.85K | -551.16K | -58.63% |
| Oct 31, 2012 | 940.01K | -63.18K | -6.30% |
| Oct 31, 2011 | 1.00M | 272.52K | 37.30% |
| Oct 31, 2010 | 730.68K | -325.12K | -30.79% |
| Oct 31, 2009 | 1.06M | -1.01M | -48.83% |
| Oct 31, 2008 | 2.06M | 1.58M | 323.77% |
| Oct 31, 2007 | 486.85K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gossamer Bio | 48.47M |
| NeurAxis | 3.57M |
| Rani Therapeutics Holdings | 1.63M |
| Kazia Therapeutics | 1.27M |
| Seres Therapeutics | 789.00K |
| aTyr Pharma | 190.00K |
ANIX News
- 4 days ago - Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - PRNewsWire
- 6 days ago - Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer - PRNewsWire
- 24 days ago - Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast - PRNewsWire
- 27 days ago - Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology - PRNewsWire
- 4 weeks ago - Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress - PRNewsWire
- 5 weeks ago - Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - PRNewsWire
- 7 weeks ago - Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation - PRNewsWire
- 7 weeks ago - EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues - Benzinga